Pfizer submits COVID-19 vaccine trial data to FDA for children aged 5-11
Pfizer and BioNTech announced they have submitted results to the U.S. Food and Drug Administration from their coronavirus vaccine trial on children aged 5 to 11. According to a statement, the results showed a "favorable safety profile." Dr. William Schaffner, a professor of infectious diseases at Vanderbilt University Medical Center, joined CBSN to discuss.